| Literature DB >> 25223381 |
Ömer Yıldız1, Ahmet Yılmaz Çoban2, Aslı Gamze Şener3, Seher Ayten Coşkuner4, Gülçin Bayramoğlu5, Hüseyin Güdücüoğlu6, Mustafa Özyurt7, Müşerref Tatman-Otkun8, Nihal Karabiber9, Nuri Özkütük10, Orhan Aktepe11, Serkan Öncü12, Uğur Arslan13, Bülent Bozdoğan14,15.
Abstract
INTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most important nosocomial pathogens and is also emerging in Turkish hospitals. The aim of this study was to determine the antimicrobial susceptibility profiles of MRSA isolated from Turkish hospitals.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25223381 PMCID: PMC4353454 DOI: 10.1186/s12941-014-0044-2
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Primers and PCR conditions used to amplify resistance genes
|
|
|
|
|
|---|---|---|---|
|
| F 5′TCT AAA AAG CAT GTA AAA GAA3′ | Pre cycle 93°C 3 min, | [ |
| R 5′CTT CGA TAG TTT ATT AAT ATT AGT3′ | 35 cycles: 93°C 60 s, 52°C 60 s, 72°C 60 s | ||
|
| F 5′GAA AAG GTA CTC AAC CAA ATA3′ | Last cycle 72°C 5 min | |
| R 5′AGT AAC GGT ACT TAA ATT GTT TAC3′ | |||
|
| F 5′GCT AAT ATT GTT TAA ATC GTC AAT TCC3′ | ||
| R 5′GGA TCA GGA AAA GGA CAT TTT AC3′ | |||
|
| F 5′GCA AAT GGT GTA GGT AAG ACA ACT3′ | Pre cycle 93°C 3 min, | [ |
| R 5′ATC ATG TGA TGT AAA CAA AAT3′ | 35 cycles: 93°C 30 s, 52°C 30 s, 72°C 60 s | ||
| Last cycles 72°C 10 min | |||
|
| F 5′GTA TTA ACT GGA AAA CAG CAA AG3′ | Pre cycle 5 dk 94°C | [ |
| R 5′GAG CTT CTT TTG AAA TAC ATG G3′ | 35 cycles 45 s 94°C, 45 s 54°C,1 min at 72°C | ||
|
| F 5′CCTACCTATTGTTTGTGGAA 3′ | Last cycle 5 min at 72°C | [ |
| R 5′ATAACGTTACTCTCCTATTC 3′ | |||
|
| F 5′GTG GAC AAA GGT ACA ACG AG3′ | Pre cycle 93oC’de 5 dk | [ |
| R 5′CGG TAA AGT TCG TCA CAC AC3′ | 35 cycles 93°C 60 s, 52°C 60 s, 72°C 60 s | ||
|
| F 5′CAG CAG ATC CTA CTC CTT3′ | Last cycle 10 min at 72°C | |
| R 5′TCG ATA GGA ACA GCA GTA3′ | |||
|
| F 5′GAG CAA TAA GGG CAT ACC AAA AAT C3′ | Pre cycle 94C’de 5 dk, | [ |
| R 5′CCG TGC ATT TGT CTT AAA AAA CTG G3′ | 35 cycles 94°C 30 s, 50°C 30 s, 72°C 30 s | ||
| Last cycle 7 min at 72°C |
MIC , and MIC values for antibiotics tested for MRSA isolates
|
|
|
|
|---|---|---|
| Tetracyclin | 128 | 128 |
| Ciprofloxacin | >64 | >64 |
| Linezolid | 2 | 2 |
| Fusidic Acid | 0.25 | 0.5 |
| Vancomycin | 1 | 2 |
| Kanamycin | >128 | >128 |
| Erythromycin | 16 | >128 |
| Lincomycin | 1 | >128 |
| Gentamycin | 64 | 128 |
Prevalence of resistance rates of 397 MRSA isolates
|
|
| ||
|---|---|---|---|
|
|
|
| |
| Erythromycin | 225 (56.7) | 64 (16.1) | 108 (27.2) |
| Lincomycin | 168 (42.3) | 66 (16.6) | 163 (41.1) |
| Tetracyclin | 350 (88.2) | 0 | 47 (11.8) |
| Ciprofloxacin | 366 (92.2) | 4 (1) | 27 (6,8) |
| Kanamycin | 363(91.4) | 1 (0.3) | 33 (8.3) |
| Gentamycin | 358 (90.2) | 5 (1.3) | 34 (8.5) |
| Fusidic Acid | 32 (8.1) | 0 | 365 (91.9) |
| Linezolid | 0 | 0 | 397 (100) |
| Vancomycin | 0 | 0 | 397 (100) |
Resistance rates by centre of MRSA isolates
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Aydın (15) | 86.6 | 100 | 0 | 0 | 0 | 100 | 80 | 60 | 93.3 |
| İzmir (17)A* | 94.1 | 100 | 0 | 5.8 | 0 | 100 | 52.9 | 64.7 | 88.2 |
| İzmir (22)B* | 95.4 | 100 | 0 | 9.1 | 0 | 90.9 | 72.7 | 63.6 | 90.9 |
| Afyon (23) | 91.3 | 86.9 | 0 | 21.7 | 0 | 86.9 | 21.7 | 26.1 | 82.6 |
| Manisa (23) | 95.6 | 86.9 | 0 | 0 | 0 | 95.6 | 69.5 | 56.5 | 91.3 |
| Van (42) | 95.2 | 97.6 | 0 | 2.4 | 0 | 95.2 | 4.7 | 2.4 | 92.8 |
| Trabzon (54) | 88.9 | 74.1 | 0 | 12.9 | 0 | 70.3 | 52.7 | 40.7 | 68.5 |
| Samsun (51) | 98 | 94.1 | 0 | 7.8 | 0 | 92.1 | 45.1 | 31.3 | 90.2 |
| Ankara (31) | 100 | 100 | 0 | 0 | 0 | 96.7 | 58 | 41.9 | 80.6 |
| Konya (28) | 92.8 | 96.4 | 0 | 10.7 | 0 | 96.4 | 89.3 | 46.2 | 92.8 |
| İstanbul (55) | 52.7 | 96.3 | 0 | 3.6 | 0 | 96.3 | 56.3 | 58.2 | 96.3 |
| Edirne (36) | 88.8 | 88.8 | 0 | 8.3 | 0 | 88.8 | 50 | 41.6 | 88.8 |
| Toplam (397) | 88.2 | 92.2 | 0 | 8.1 | 0 | 91.4 | 56.7 | 42.3 | 90.2 |
*A: Katip Celebi University Bozyaka Hospital, B: Izmir Atatürk State Hospital.
**Tetra, Tetracycline; Cipro, Ciprofloxacin; Line, Linezolid; F. Acid, Fusidic Acid; Vanco, Vancomycin; Kana, Kanamycin, Erythro, Erythromycin; Linco, Lincomycin; Genta; Gentamycin.
Distribution of resistance genes
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
| Gene (%) |
|
|
|
| ND** | ND | ND | ND | ND |
|
|
|
| |||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
| ||||||||
|
|
|
| |||||||
| Unknown (6.6) | Unknown (4.7) | Unknown (7.1) | Unknown (7) | ||||||
*Erythro, Erythromycin; Linco, Lincomycin; Tetra, Tetracycline; Genta, Gentamycin; Cipro, Ciprofloxacin; Line, Linezolid; F. Acid, Fusidic Acid; Vanco, Vancomycin; Kana, Kanamycin.
**ND; Not Determined.